Trials / Recruiting
RecruitingNCT07067905
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-XT771 | 68Ga-XT771 is injected intravenously with a dose of 4-8 mCi |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2026-04-01
- Completion
- 2026-06-01
- First posted
- 2025-07-16
- Last updated
- 2025-07-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07067905. Inclusion in this directory is not an endorsement.